| Literature DB >> 34204857 |
Sweta Bhambhani1, Kirtikumar R Kondhare1,2, Ashok P Giri1,2.
Abstract
Phytochemicals belonging to the group of alkaloids are signature specialized metabolites endowed with countless biological activities. Plants are armored with these naturally produced nitrogenous compounds to combat numerous challenging environmental stress conditions. Traditional and modern healthcare systems have harnessed the potential of these organic compounds for the treatment of many ailments. Various chemical entities (functional groups) attached to the central moiety are responsible for their diverse range of biological properties. The development of the characterization of these plant metabolites and the enzymes involved in their biosynthesis is of an utmost priority to deliver enhanced advantages in terms of biological properties and productivity. Further, the incorporation of whole/partial metabolic pathways in the heterologous system and/or the overexpression of biosynthetic steps in homologous systems have both become alternative and lucrative methods over chemical synthesis in recent times. Moreover, in-depth research on alkaloid biosynthetic pathways has revealed numerous chemical modifications that occur during alkaloidal conversions. These chemical reactions involve glycosylation, acylation, reduction, oxidation, and methylation steps, and they are usually responsible for conferring the biological activities possessed by alkaloids. In this review, we aim to discuss the alkaloidal group of plant specialized metabolites and their brief classification covering major categories. We also emphasize the diversity in the basic structures of plant alkaloids arising through enzymatically catalyzed structural modifications in certain plant species, as well as their emerging diverse biological activities. The role of alkaloids in plant defense and their mechanisms of action are also briefly discussed. Moreover, the commercial utilization of plant alkaloids in the marketplace displaying various applications has been enumerated.Entities:
Keywords: alkaloid; biological activity; classification; defense; enzyme; modification
Mesh:
Substances:
Year: 2021 PMID: 34204857 PMCID: PMC8199754 DOI: 10.3390/molecules26113374
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Classification of alkaloids. Alkaloids biosynthesized in plants are classified based on their biochemical precursors (biosynthetic pathway), chemical structures, and according to their occurrence in different genera of the plant kingdom.
| Group | Characteristic | Representative Compounds | Plant Source | Reference |
|---|---|---|---|---|
| Feature | ||||
|
| ||||
|
| Tyrosine acts as precursor | Berberine | [ | |
|
| Tryptophan acts as precursor | Ajmalicin | [ | |
| strychnine, brucine |
| |||
|
| Ornithine acts as precursor | Senecionine | [ | |
|
| Scopolamine | |||
|
| Lysine acts as precursor | Piperine | [ | |
|
| Lupinine |
| ||
| Cytisine | ||||
|
| Swainsonine | |||
|
| L-Aspartate acts as precursor | Nicotine | [ | |
|
| Cerpegin | |||
|
| Anthranillic acid acts as precursor | Skimmianine | [ | |
| Camptothecin | ||||
|
| Vasicine | |||
|
| Adenosine (SAM cycle) acts as precursor | Theobromine | [ | |
| Caffeine | ||||
|
| Formed by the inclusion of one or two nitrogen atoms to a preformed steroid molecule | Veratridine, jervine and cyclopamine; | [ | |
| Zygacine | ||||
|
| Formed by the introduction of a nitrogen atom from methylamine, ethylamine, or β-aminoethanol to terpenoidal skeletons | Secodaphniphyllate |
| [ |
| Aconitine | ||||
|
| Formed by the linkage of a structure consisting of a nitrogen system to the “A” ring | Rohitukine | [ | |
| Dysoline |
| |||
| Cassiadinine |
| |||
| Ficine and isoficine |
| |||
|
| capitavine |
| ||
| Aquiledine, isoaquiledine |
| |||
|
| ||||
|
| Mononuclear | Hygrine |
| [ |
| Boldine | ||||
| Polynuclear | Atropine | |||
| Reserpine |
| |||
| Quinine |
| |||
|
| Phenylethylamine skeleton | Ephedrine | [ | |
| Capsaicin | ||||
| Tropolone skeleton | Colchicine | |||
| Modified diterpenes | Paclitaxel | |||
|
| ||||
|
| Present in the Papaveraceae family | Morphine, codeine, papeverine, and thebaine |
| [ |
|
| Present in the Solanaceae family | Solanine, tomatidine, and solasodamine | [ | |
|
| Present in the Daphniphyllaceae family | Daphniphylline, daphilactone-B |
| [ |
|
| Present in the Apocynaceae family | Catharanthine leurosine, vincristine, and vinblastine |
| [ |
|
| Present in Annonaceae Ranunculaceae, Berberidaceae, Menispermaceae families; shares the same protoberberine skeleton | Berberine | [ | |
| Jatrorrhizine | ||||
| Palmatine | ||||
|
| Present in Ephedra genus of the Ephedraceae family | Ephedrine | [ | |
Figure 1Examples of alkaloids biosynthesized from the common skeleton. Multiple alkaloids are biosynthesized from the common skeleton represented inside the blue circle in different plant species. (A) Benzylisoquinoline alkaloids in Sacred lotus; (B) Steroidal alkaloids and their glycosides in tomato, potato, and eggplant; (C) Terpene indole alkaloids in C. roseus. The common skeleton undergoes multiple enzymatic conversions (M = methylation, O = oxidation, R = reduction, G = glycosylation, A = acetylation, H = hydroxylation, and E = epoxidation) represented by multiple arrows to form a variety of alkaloids. Key enzymatic reactions that are reported have been mentioned beside the arrows. The chemical structures of alkaloids are drawn from “ChemSpider: the Free Chemical Database”.
Figure 2Alkaloid diversity in the plant kingdom. Alkaloids are produced in various parts of plants (such as the leaves, roots, seeds, etc.). Alkaloids are transported to required tissues mainly in response to various stress signals perceived from the environment. In the biosynthesis of alkaloids, enzymes of different families (MT: methyl transferase; GT: uridine-diphosphate-glycosyl transferase; AT: acyl transferase; CYP: cytochrome P450-monooxygenase and -reductase; SDR: short-chain dehydrogenase/reductase) act on alkaloidal substrates to generate diverse alkaloids with certain chemical modifications in numerous plant species. These enzymes catalyze the modification of alkaloidal substrates represented as A, B, C, D, and E in the presence of donors. SAM-S-adenosyl methionine acts as methyl donor for MTs; UDP-Glucose (UDP-Glc), UDP-rhamnose (UDP-Rha), UDP-xylose (UDP-Xyl), UDP-galactose (UDP-Gal), and UDP-glucuronic acid (UDP-GlcUA) are sugar donors for UDP-GTs; acyl-CoA thioesters and 1-O-β-glucose esters are acyl donors for ATs; NAD(P)H acts as an electron donor for CYPs and SDRs. Plant image is retrieved from BioRender (BioRender.com) (accessed on 20 March 2021). The chemical structures of alkaloids are drawn from “ChemSpider: the Free Chemical Database”.
Figure 3Examples of chemical reactions taking place in alkaloid biosynthesis in plants. Enzymes catalyzing various reactions are indicated in blue. Red dotted circles indicate the addition of functional entities at the respective positions. (A) Methylation reactions in the biosynthesis of alkaloids in genus Corydalis, SoOMT1: scoulerine 9-O-methyltransferase, CoOMT: columbamine O-methyltransferase; (B) Methylation reactions in the biosynthesis of alkaloids in Sacred lotus, NnOMT5: O-methyltransferase 5, CNMT: coclaurine N-methyltransferase; (C) Glycosylation reactions in the biosynthesis of steroidal glycoalkaloids in Solanum lycopersicum, SlGAME: glycoalkaloid metabolism; (D) Acetylation reaction in the biosynthesis of morphinan alkaloids, SalAT: salutaridinol 7-O-acetyltransferase; (E) Acetylation reaction in the biosynthesis of cocaine; (F) Oxidative para-para phenol coupling reaction in the biosynthesis of colchicine; (G) Hydroxylation reaction followed by epoxidation reaction in the biosynthesis of tropane alkaloids, H6H: hyoscyamine 6β-hydroxylase; (H) Reduction reactions catalyzed by two stereospecific reductases in the biosynthesis of tropane alkaloids, TR-I/II: tropinone reductase I/II; (I) Reduction reaction in the biosynthesis of morphinan alkaloids, COR: codeinone reductase. The chemical structures of alkaloids are drawn from “ChemSpider: the Free Chemical Database”.
Figure 4The role of alkaloids in plant defense. Alkaloids produced in different plant tissues, such as leaves, roots, bark, and seeds, are transported to local tissues for fighting against various predators such as pests, fungi, bacteria, and insect larvae, providing plants with protection against these predators. Alkaloids also stop the growth of other plants in the vicinity (allelopathy). Individual images of plant and predators are retrieved from BioRender (BioRender.com) (accessed on 20 March 2021).
Figure 5The mechanism of action of alkaloids. Alkaloids act as a chemical barrier that protects plants from predators, such as herbivorous insects and vertebrates; pathogenic bacteria and fungi; and parasitic plants. Various mechanisms employed by plants using alkaloids create harmful effects in predators and are depicted in the figure.
The biological activities of alkaloids. Numerous biological activities of alkaloids present in plants, their mechanism of action, and IC50 values are listed.
| Alkaloid | Biological Activities | Mechanism of Action | IC50 Range | References |
|---|---|---|---|---|
|
| Antineoplastic and antimicrotubule | Suppresses microtubule dynamics by binding to β-tubulin subunits of microtubule and thereby inhibiting spindle function. | 0.00126–12.3 µM | [ |
|
| Antileukemic, antilymphoma, antineuroblastoma, and antisarcoma | Inhibits mitosis at the metaphase stage by interacting with tubulin; interferes with amino acids, cyclic AMP, glutathione metabolism, and calmodulin-dependent Ca2+-transport ATPase activity. | 0.00126–1.01e + 3 µM | [ |
|
| Antitopoisomerase and anti-HIV | Causes DNA damage by binding to topoisomerase I and the DNA complex forming a ternary complex, stabilizing it, and preventing DNA re-ligation resulting in apoptosis. | 0.00214–62.3 µM | [ |
|
| Anti-inflammatory, anti-fertility, anti-implantation, anti-cancer, and immuno-modulatory | Triggers apoptosis in lung cancer cells. | 0.3–7.3 μM | [ |
|
| Neurotoxic, pesticidal, and rodenticidal | Acts as an antagonist of glycine (an inhibitory neurotransmitter) and acetylcholine receptors, thereby preventing inhibitory signals and activating motor neurons in the spinal cord, resulting into spastic muscle contraction. | 64–92 nM | [ |
|
| Promotes short-term weight loss, decreases motion sickness, possesses a cardiac stimulant, hyperglycaemic, hypertensive, bronchodilator | Indirectly stimulates the adrenergic receptor system by increasing the activity of norepinephrine at the postsynaptic α and β receptors. Acts as a CNS stimulant, due to its ability to cross the blood-brain barrier. | 124 μM | [ |
|
| Anti-gout, anti-inflammation, and treats familial Mediterranean fever | Inhibits mitosis by inhibiting microtubule polymerization; inhibits proinflammatory mechanisms and increases anti-inflammatory mediators; inhibits neutrophil motility and activity, interferes with superoxide formation, and thereby inhibits or prevents gout inflammation. | 3–300 nM | [ |
|
| Bronchodilator, mucolytic, antitussive, antibacterial, cytotoxic, abortifacient, and uterotonic | Acts as an acetylcholinesterase inhibitor and a butyrylcholinesterase inhibitor. | 125 μM | [ |
|
| Anti-hypertensive and anti-psychotic | Interferes with the sequestering of neurotransmitters into storage vesicles located in the presynaptic neuron by inhibiting their ATP/Mg2+ pump, causing a reduction in catecholamines, thereby causing antihypertensive effects. | 1.7–2.8 μM | [ |
|
| Anti-hypertensive | Acts as α1-adrenergic receptor antagonist and shows hypotensive effects. | 3.5–5.44 μM | [ |
|
| Anti-inflammatory, immunologic, anti-allergenic, and anti-tumour; used for treating Ebola virus infection in mice | Acts as a calcium-channel blocker, inhibits the degranulation of mast cells. | 11.3 μM | [ |
|
| Analgesic and CNS stimulant | Acts as agonists for mu and kappa opioid receptors, on the ventral tegmental area of the brain; agonist of the delta-opioid receptor in the nucleus accumbens and activates the morphine reward pathway. | 1–8.8 mM | [ |
|
| Analgesic, antidiarrheal, and antitussive | Acts as agonist for mu opioid receptors involved in the transmission of pain throughout the body and central nervous system. | 60 μM | [ |
|
| Vasodilatory and antispasmodic | Shows direct vasodilating action on cerebral blood vessels, increases cerebral blood flow and decreases cerebral vascular resistance. | 2–37 μM | [ |
|
| Antimicrobial, antitumor, anti-hyperglycemic, antimalarial, and anti-inflammation; Alzheimer’s disease treatment | Lowers cholesterol through LDL-receptor-mediated liver LDL cholesterol clearance, promotes LDL-receptor expression through the proprotein convertase subtilisin/kexin type 9 (PCSK9)-LDL-receptor pathway. | 0.1–25 µM | [ |
|
| Depressant action on sympathetic nervous system; possesses mydriatic, spasmolytic, and local anesthetic effects; treats motion sickness, postoperative nausea, and vomiting | Acts as a non-selective competitive inhibitor of M1-M5 mAChRs (G-protein-coupled muscarinic acetylcholine receptors), shows anticholinergic effect, and alters signalling through CNS associated with vomiting. | 928 µM | [ |
|
| Presents hemo-preventive, anti-carcinogenic, antioxidant, anti-inflammatory, anticarcinogenic, stimulatory, hepatoprotective, antihyperlipidemia, anti-asthmatic activities; gastro-intestinal stimulant, and appetite stimulant | Affects the plasma concentrations of P-glycoprotein in the (P-gp)-mediated transport of drugs and metabolizes enzyme CYP3A4 substrates in humans; lowers endogenous UDP-glucuronic acid contents and inhibits transferase activity, thereby modifying the rate of glucuronidation. | 1–34 μM | [ |
|
| Insecticidal | Reversible inhibitor of acetylcholinesterases; possesses a binding affinity for muscarinic and nicotinic acetylcholine receptors. | 712 μM | [ |
|
| Chemotherapeutic | Acts as a golgi α-mannosidase II inhibitor | 34 nM | [ |
|
| Analgesic, antispastic, sedative, and anti-inflammatory | Suppresses TNF-α and IL-6 gene transcription, inhibits the production of NO, prostaglandin E2, and superoxide anions. | 8.6 μg/mL | [ |
|
| Antitumor, bronchorelaxater, and antitussive | Acts as antagonist to adenosine-receptors within the plasma membrane of virtually every cell, which further promotes neurotransmitter release. | 2500 µM | [ |
|
| Autonomous nervous system stimulant, anti-inflammation; improves cognitive performance | Inhibits the activity of nucleotide phosphodiesterase enzymes, regulates calcium handling in cells, and participates in adenosine receptor antagonism, stimulating inotropic effects in the heart. | 500–1000 μM | [ |
|
| Antiherbivore, insecticide, teratogenic, addictive, stimulant, and anxiolytic effects; treatment of nicotine dependence | Acts as an agonist/antagonist of certain nicotinic acetylcholine receptors, binding with receptors leading to depolarization, activating voltage-gated calcium channels. | 0.5–20 nM | [ |
|
| Inhibitor of sodium channel inactivation and neurotoxic | Depolarizes cells by affecting sodium channels, can activate Nav 1.8 along with additional Nav channels; enhances protein tyrosine phosphorylation; can turn the membrane potential to a more positive one and can also modify the effect of progesterone on (a2+)i and sperm membrane potential. | 27–84 µM | [ |
|
| Analgesic, blood coagulant, anti-inflammatory, cardiotoxic, and neurotoxic | Interacts with voltage-dependent sodium-ion channels, binds to the channel at the neurotoxin binding site 2 on the α-subunit, suppressing the conformational change in the sodium-ion channel from an active state to an inactive state. | 10–20 µM | [ |
|
| Sedative, hypnotic laxative, and diuretics | Not known. | Not reported | [ |
|
| Antioxidant, antipyretic, anti-inflammation, hepatoprotectant, cytoprotectant, and neuroprotectant | Acts as an α-adrenergic antagonist in vascular tissues; it can cross the blood-brain barrier exhibiting neuroprotective effects. | 8.5 µM | [ |
|
| Anticholinergic, antispasmodic, and antimuscarinic | Binds and inhibits muscarinic acetylcholine receptors, producing anticholinergic effects. | 2–55 µM | [ |
|
| Anti-obesity, antifungal action, and chemical irritant; treating peripheral neuropathy, psoriasis, and non-allergic rhinitis | Induces a topical hypersensitivity reaction on the skin by carrying out the “defunctionalization” of nociceptor fibers. Pain mechanism is due to temporary loss of membrane potential, inability to transport neurotrophic factors, and the reversible retraction of epidermal and dermal nerve fiber terminals. | 50 μM | [ |
|
| Antiallergic, anti-inflammation, antipyretic, and anti-carcinogen; treating gastrointestinal and neurological disorders | Inhibits cholinesterase activity, disrupts cell membranes; opens the potassium channels of the mitochondria increasing their membrane potential, followed by the transport of Ca2+ from mitochondria into the cytoplasm leading to the an increased concentration of Ca2+ in the cytoplasm triggering cell damage and apoptosis. | 32.18 μM | [ |
|
| Anti-leukemia, fungicide, antimicrobial, and insecticide | Causes the disruption of cellular membranes and the inhibition of acetylcholinesterase; stimulates the immune system by participation in a sequence of respiratory burst destroying bacteria. | 7–10 μM | [ |
|
| Antibacterial and antifungal | Blocks α-1 and α-2 adrenoreceptors and monoamine oxidase A and B. | 4–62 μM | [ |
|
| Antimicrobial, hypoglycemic, antiarrhythmic, and antioxidant | Intercalates with nucleic acids; induces apoptosis; inhibits proliferation. | 0.07–22 µM | [ |
|
| Antimalaria, mild antipyretic, and analgesic | Interferes with a parasite’s ability to break down and digest hemoglobin, leading to starvation in parasites. | 13.4 µM | [ |
|
| Teratogenic | Partial agonist of α4-β2 nicotinic acetylcholine receptors; causes a reduction in the effects of nicotine on dopamine release in the mesolimbic system when given alone, while simultaneously attenuates nicotine withdrawal symptoms accompanying cessation attempts. | 27.3 nM | [ |
Commercial applications of plant alkaloids. Approved formulations of alkaloids and their potential applications have been listed. Information about the formulations has been retrieved from web sources.
| Application | Constituent Alkaloid | Formulation Names |
|---|---|---|
| Chemotherapy | Paclitaxel | Taxol®, Taxotere®; |
| Vinorelbine prepared from vindoline and catharanthine | Navelbine®; | |
| Vinblastine | Velban®; | |
| Vincristine | Vincasar Pfs®, Oncovin®; | |
| Camptothecin | Camptosar® | |
| Gout treatment | Colchicin | Colcrys, Mitigare, Gloperba |
| Respiratory ailments treatment | Vasicine | Ayusas Adulsa Cough syrup; |
| Codeine | Ambenyl®, Calcidrine, Neo AC cough syrup; | |
| Capsaicin | Nasol Nasal sprayTM | |
| Hypertension treatment | Reserpine | Diupres-250, Diupres-500, Regroton®, Demi-Regroton; |
| Ajmalicine | Isosarpan, Iskedyl, Isquebral, Duxil, Duxor, Saltucin Co, Salvalion, Sarpan; | |
| Anesthetic premedication, toxicity antidotes | Atropine | Atropen |
| Antimuscarinic agents | Atropine | Isopto Atropine, Vistatropine Eye Drops |
| Analgesic agents | Morphine | Kadian, Kadian ER, Morphabond, Oramorph SR, |
| Roxanol; | ||
| Codeine | Emperine 3; | |
| Capsaicin | Capsitop O Roll ON, Zostrix, Capzasin-HP, Axsain, Rid-A-Pain, Salonpas Hot, Medigrip Capsicum Plaster | |
| Cardiac ailment treatment | Papaverin | Pavabid® (Marion), PapaverTM |
| Malaria treatment | Quinine | Qualaquin, |
| Scalp repairment | Capsaicin | Thermascalp |
| Nutritional supplement | Ephedrine | ECA Stack; |
| Berberine | Berberta, Myobery Tablet, Berberine Glucose Support, Berbitol Tablet; | |
| Piperine | SuperbTM Qp, Rhodiola, Dezcumin | |
| Vincamine | Oxybral SR, Brain Ox, Vincabral SR | |
| Smoking cessation | Cytosine | Tabex |
| Nicotine | Nicotex Nicotine Gum, | |
| STOP-NIC Nicotine Gum, Nixit-Nicotine Gum | ||
| Pesticide | Strychnine | Boomer-Rid, Certox, Dog-button, Dolco mouse Ceral, Stricnina, Mole death, Mouse-nots, Strychnos |